ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ УСТЕКИНУМАБА ПРИ БОЛЕЗНИ КРОНА (обзор литературы)

Болезнь Крона (БК) является хроническим аутоиммунным заболеванием желудочно-кишечного тракта, которое поражает, в основном, молодых людей трудоспособного возраста. До сих пор пациенты с данным заболеванием не могут быть вылечены ни с помощью консервативной терапии ни хирургическими методами. Эффективность препаратов, доступных для лечения БК, ограничена. Кроме того, их применение нередко сопровождается нежелательными явлениями. Все это рождает потребность в новых препаратах, принципиально отличающихся по механизму действия, с высокой эффективностью и хорошим профилем безопасности. Данный обзор посвящен новому биологическому препарату для лечения БК, направленному на блокирование интерлейкинов 12 и 23, которые задействованы в патогенезе воспаления при ВЗК. В обзоре представлены данные клинических испытаний препарата 2 и 3 фазы и данные, полученные в клинической практике, позволяющие делать выводы об эффективности и безопасности данного препарата, а также его месте в алгоритме лечения больных с БК.

1. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017; № 2, с. 7-29.

2. Халиф И.Л. Изменения в клинических рекомендациях по диагностике и лечению больных ВЗК. Поликлиника. 2017; 3: с. 20-26.

3. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn’s disease management: Need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6 Suppl.2:S224-234.

4. Chaparro M, Ordas I, Cabre E, Garcia-Sanchez V,et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term followup study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404-1410.

5. Domenech E, Manosa M, Navarro M, Masnou H, et al. Long-term methotrexate for Crohn’s disease: Safety and efficacy in clinical practice. J Clin Gastroenterol. 2008;42:395-399.

6. Gonzalez-Lama Y, Taxonera C, Lopez-Sanroman A, Perez-Calle JL, et al. Methotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. Eur J Gastroenterol Hepatol. 2012;24:1086-1091.

7. Белоусова Е.А., Морозова А.Н., Никитина Н.В. Инфликсимаб (Ремикейд) в лечении рефрактерных форм болезни Крона. Российский медицинский журнал. 2006; № 1, с. 28-32.

8. Халиф И.Л., Шапина М.В. Применение ведолизумаба при воспалительных заболеваниях кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; № 6, с. 92-100.

9. Шапина М.В., Халиф, И.Л., Нанаева Б.А. Применение цертолизумаба пэгола при болезни Крона (обзор литературы). Колопроктология. 2016; № 3,с. 102-108.

10. Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn’s disease: results from the UNITI-1 and UNITI-2 studies [abstract no. OP028]. J Crohns Colitis. 2016;10(Suppl 1):S23–4.

11. Ben-Horin S, Chowers Y. Review article: Loss of response to antiTNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33:987-995.

12. Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res. 2014;163:533-556.

13. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, et al. Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660.

14. Халиф И.Л., Шапина М.В. Биологическая (антицитокиновая) терапия при болезни Крона: эффективность и потеря ответа. Доказательная гастроэнтерология. 2013; № 3, с. 13-23.

15. Chaparro M, Panes J, Garcia V, Manosa M et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose «escalation» in patients losing response. J Clin Gastroenterol. 2011;45:113-118.

16. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: Results from the CHARM trial. Am J Gastroenterol. 2009;104:1170-1179.

17. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: A review. Am J Gastroenterol. 2009;104:760-767.

18. Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol. 2014;20: 1139-1146.

19. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404.

20. Lowenberg M, d’Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep. 2013;15:311.

21. Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600.

22. Simon EG, Ghosh S, Iacucci M, Moran GW. Ustekinumab for the treatment of Crohn’s disease: Can it find its niche? Therap Adv Gastroenterol. 2016;9:26-36.

23. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: New immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58:1152-1167.

24. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006;12:5606-5610.

25. Kavanaugh A, Ritchlin C, Rahman P, Puig L, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000-1006.

26. Toichi E, Torres G, McCormick TS, Chang T, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/ IL-23 in psoriasis. J Immunol. 2006;177:4917-4926.

27. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov Med. 2012;14:253-262.

28. Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: What are the data? United European Gastroenterol J. 2015;3:419-428.

29. Schmitt H, Billmeier U, Dieterich W, Rath T, et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease.Gut.2019;68(5):814-828. doi: 10.1136/gutjnl-2017-315671.

30. Benson JM, Peritt D, Scallon BJ, Heavner GA et al. Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535-545.

31. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008;57:1682-1689.

32. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719-729.

33. Инструкция по применению препарата Стелара (ЛСР-006465/09) от 12.04.19, Электронный ресурс: http://grls. rosminzdrav.ru

34. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR et al. Ustekinumab Crohn’s Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135: 1130–1141.

35. Sands BE, Feagan BG, Rutgeerts P, Colombel JF et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618-627, e613.

36. Sandborn WJ, Rutgeerts P, Gasink C et al. Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65–77. https://doi. org/10.1111/apt.14794

37. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946-1960.

38. Shelton E, Allegretti JR, Stevens B, Lucci M et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis. 2015;21:2879-2885.

39. Sands BE, Gasink C, Jacobstein D, Gao LL et al. Efficacy and safety of dose adjustment and delayed response to ustekinumab in moderate-severe Crohn’s disease patients: Results from the IM-UNITI maintenance study. United European Gastroenterol J. 2016;4:OP005.

40. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711-721.

41. Wils P, Bouhnik Y, Michetti P, Flourie B et al. Long-term efficacy and safety of ustekinumab in refractory Crohn’s disease patients: A multicenter retrospective experience. J Crohns Colitis. 2017;11 Suppl.1: S43

42. Li K, Chan D, Pollack P, Jacobstein D, et al. Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn’s disease. Gastroenterology. 2017;152Suppl.1.:S595.

43. Battat R, Kopylov U, Bessissow T, Bitton A, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15:1427-1434.

44. Ma C, Fedorak RN, Kaplan GG, Dieleman LA, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: Real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232-1243.

45. Wils P, Bouhnik Y, Michetti P, Flourie B, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242-250.e1-2.

46. Khorrami S, Ginard D, Marin-Jimenez I, Chaparro M, et al. Ustekinumab for the treatment of refractory Crohn’s disease: The Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662-1669.

47. Kopylov U, Afif W, Cohen A, Bitton A et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experience. J Crohns Colitis. 2014;8:1516-1522.

48. Gottlieb AB, Kalb RE, Langley RG, Krueger GG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): Experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441-1448.

49. Papp K, Gottlieb AB, Naldi L, Pariser D et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14:706-714.

50. Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961-969.

51. Loftus EV, Sloan S, Ramachandran P, Yang Z et al. Comparison of rates of active tuberculosis infection in the phase 2 and 3 trial programs for ANTI-IL12/23 and ANTI-TNF. Gastroenterology. 2017;1 52Suppl.1.:S596.

52. Rolston VS, Kimmel J, Hudesman D, Chang S, Bosworth BP, Popov V. Adverse events with use of ustekinumab: A systematic review and meta-analysis. Gastroenterology. 2017;152Suppl.1.:S578-579.

53. Ginard D, Khorrami S, Marín I, Chaparro M, et al. One-year outcomes of ustekinumab therapy in a multi-drug refractory Crohn’s disease cohort. ECCO. 2013:P425.

54. Kimball AB, Guenther L, de Jong E, Kalia S, et al. Pregnancy outcomes in women with moderate to severe psoriasis: The PSOLAR experience. J Am Acad Dermatol. 2015;EADV: P1781.

55. Cortes X, Borras-Blasco J, Antequera B, Fernandez-Martinez S, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: A case report and review of the literature. J Clin Pharm Ther. 2017;42:234-236.

56. Galli-Novak E, Mook SC, Buning J, Schmidt E, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191-192.

57. Feagan B, Gasink C, Gao LL, Blank M, et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase 2 b study of ustekinumab in patients with moderately to severely active Crohn’s disease. J Crohn’s Colitis. 2012;6 Suppl. 1:S129-130.

58. Gasink C, Chan D, Gao LL, Schenkel B, Han C. Assessment of sleep impairment in patients with Crohn’s disease: Results from the Ustekinumab Certifi Study. Gastroenterology. 2013;144 Suppl. 1:S231.

59. Sands BE, Han C, Gasink C, Szapary P et al. Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn’s disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials. Gastroenterology. 2016;150 Suppl. 1:S1004.

60. Sandborn WJ, Sands BE, Gasink C, Yeager B et al. Reduced Rates of Crohn’s-Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years. Gastroenterology. 2018;154Suppl.1.:S377-378.

61. Gottlieb A, Menter A, Mendelsohn A, Shen YK, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, doubleblind, placebo-controlled, crossover trial. Lancet. 2009;373: 633-640.

62. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S et al. AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF- biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology 2013; 145: 1459–1463.

63. Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613-623.

64. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007; 357: 239–250.

65. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А. и соавт. Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности, терапевтической эффективности и применению генно-инженерных биологических препаратов у пациентов с сочетанными иммуновоспалительными заболеваниями (псориаз, псориатический артрит, болезнь Крона). Современная ревматология. 2018; № 12(3), с. 4-18.

66. Armuzzi A, Ardizzone S, Biancone L, et al. Ustekinumab in the management of Crohn’s disease: Expert opinion. Digestive and Liver Diseases. 2018;50(2):653-660.

67. Danese S, Bonovas S, Peyrin-Biroulet L. Positioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practice. Jornal of Crohn’s and Colitis, 2017, 1-9 doi:10.1093/ecco-jcc/jjx079.

68. Pacou M, Mesana L, Gauthier A, Naessens D et al. Indirect treatment comparison of ustekinumab versus other biologics in moderate to severe Crohn’s disease: A 1-year treatment sequence analysis. Value Health. 2016;19:A576.

69. Tillack C, Ehmann LM, Friedrich M, Laubender R, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014; 63: 567–577.

70. Инструкция по применению препарата Ремикейд (П N012948/01) от 15.11.11, Электронный ресурс: http://grls. rosminzdrav.ru

71. Инструкция по применению препарата Энтивио (ЛП-003697) от 22.02.16, Электронный ресурс: http://grls.rosminzdrav.ru